Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets Platinum-Resistant ovarian cancer

NCT ID NCT04516447

Recruiting now Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive different drug combinations to find the safest dose and check for side effects. The goal is to control the disease, not cure it, as ongoing treatment is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOID FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma peritoneum cancer primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER PERITONEAL CANCER SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site 0103

    RECRUITING

    Houston, Texas, 77030, United States

  • Site 0104

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Site 0111

    RECRUITING

    St Louis, Missouri, 53110, United States

  • Site 0173

    RECRUITING

    New York, New York, 10029, United States

  • Site 0191

    RECRUITING

    Providence, Rhode Island, 02905, United States

  • Site 0196

    COMPLETED

    Nashville, Tennessee, 37203, United States

  • Site 0259

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Site 0264

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Site 1001

    COMPLETED

    Banja Luka, 78000, Bosnia and Herzegovina

  • Site 1002

    COMPLETED

    Sarajevo, 71000, Bosnia and Herzegovina

  • Site 1003

    COMPLETED

    Tuzla, 75000, Bosnia and Herzegovina

  • Site 1201

    COMPLETED

    Sofia, 1632, Bulgaria

  • Site 1202

    COMPLETED

    Panagyurishte, 4500, Bulgaria

  • Site 1401

    COMPLETED

    Tbilisi, 0112, Georgia

  • Site 1902

    COMPLETED

    Belgrade, 11080, Serbia

  • Site 2705

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Site 2706

    RECRUITING

    Melbourne, Victoria, 3144, Australia

  • Site 2707

    COMPLETED

    South Brisbane, Queensland, 4101, Australia

  • Site 2708

    COMPLETED

    Sunshine Coast, Queensland, 4556, Australia

  • Site 2709

    COMPLETED

    Adelaide, South Australia, 5000, Australia

  • Site 2716

    RECRUITING

    Melbourne, Victoria, 3121, Australia

  • Site 2901

    COMPLETED

    Busan, South Korea

  • Site 2903

    COMPLETED

    Seoul, 03080, South Korea

  • Site 2904

    COMPLETED

    Seoul, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.